Differential diagnostic value of combined detection of serum HE4 and CA125 in patients with endometrial carcinoma from benign uterus tumor

Background and purpose:To date,there is no good marker for screening or disease monitoring of endometrial carcinoma.The present study aimed to investigate the significance of human epididymis protein 4(HE4) as a tumor marker combined with CA125 in diagnosis of endometrial carcinoma patients.Methods:Serum levels of HE4 and CA125 were examined in 80 patients with endometrial carcinoma.Twenty-seven patients with benign uterus disease were used as controls.Results:Serum levels of HE4 in endometrial carcinoma group were significantly higher than those in the benign uterus disease group(92.32±7.60 pmol/L vs 58.88±3.01 pmol/L,P0.0001),while the difference of these CA125 levels have no statistical meaning(30.05±5.24 U/mL vs 34.32±8.16 U/mL,P0.05).The receiver operating characteristic area under the curve(ROC-AUC) were 0.731,0.503 and 0.758,the sensitivity were 32.5%,10% and 33.8% when the specificity was 95% in HE4 alone,CA125 alone and HE4+CA125 combined detection in endometrial cancer group.Conclusion:HE4 is an ideal tumor marker and it has certain values in accessory diagnosis and differential diagnosis of endometrial cancer.The clinical value can be improved by combined detection of HE4 and CA125.